Post by Brindha Chandrasekaran
38K+ Followers | Subject Matter Expert | Corporate Trainer | Author | Consultant | Keynote Speaker | Mentor | Clinical Research | Oncology | CDx | Precision Medicine | Competitive Intelligence | Career Guidance
T Cells vs. Cancer Cells ⚡ In this video (killing assay), we observe an active battle between T cells, a type of immune cell, and cancer cells. The cancer cell line depicted is MC38-OVA, a genetically modified colon cancer cell line engineered to express the ovalbumin (OVA) model antigen. This antigen is used to study immune responses in cancer research. T cells, specifically cytotoxic T lymphocytes (CTLs), are trained to recognize and eliminate cells that express certain foreign or abnormal antigens, like OVA. In this assay, the T cells are able to identify the MC38-OVA cancer cells as targets and initiate the killing process by releasing cytotoxic molecules. These molecules induce apoptosis (programmed cell death) in the cancer cells, effectively neutralizing them. This type of experiment allows researchers to study the immune system's ability to target cancer cells, providing valuable insights for immunotherapy development. VC: To Original Owners
Video Content